广东医学2018，Vol.39Issue(8)：1213-1217,1222,6.
TAI联合索拉非尼和单用索拉非尼对伴门脉主干或主分支癌栓的肝癌的疗效比较
Sorafenib combined with transcatheter arterial infusion versus sorafenib alone for hepatocellular carcinoma with major portal vein carcinoma thrombosis
摘要
Abstract
Objective To compare the efficacy and safety of sorafenib combined with transcatheter arterial infu -sion (TAI) and sorafenib alone for hepatocellular carcinoma (HCC) with major portal vein carcinoma thrombosis .Meth-ods A total of 73 patients with HCC were randomly divided into sorafenib combined with TAI (SorTAI) group (n＝36) and sorafenib group (n＝37).The patients in the sorafenib group were treated with sorafenib 400 mg orally twice a day. The patients in the SorTAI group were treated with sorafenib 400 mg orally twice a day and TAI of oxaliplatin , leucovorin and 5-fluorouracil (FOLFOX), repeated every 21 days.The primary endpoint was the overall survival (OS).The sec-ondary endpoint was tumor response , progression free survival (PFS) and adverse events (AEs).Results The OS in the SorTAI group was significantly better than that in the sorafenib group (10.218 months vs.7.133 months, P＝0.002). The PFS in the SorTAI group was also significantly better than that in the sorafenib group (5.651 months vs.3.067 months, P＝0.019).In the SorTAI group, 4 patients achieved conversion to complete resection after the study treatment , and one of them experienced a pathological complete response .Treatment-related deaths did not occur in both groups . There were more mild neurotoxicity , bone marrow suppression and hepatic decompensation cases in the SorTAI group , but most of them can be recovered .Only one patient terminated treatment because of bone marrow suppression .Conclusion Sorafenib combined with TAI of FOLFOX might be a feasible and promising treatment for HCC with major portal vein carci -noma thrombosis.关键词
肝细胞癌/门脉主干或主分支癌栓/肝动脉灌注化疗/索拉非尼/FOLFOXKey words
hepatocellular carcinoma/major portal vein carcinoma thrombosis/transcatheter arterial infusion/sorafenib/FOLFOX引用本文复制引用
余紫珊,何敏柯,张耀军,石明..TAI联合索拉非尼和单用索拉非尼对伴门脉主干或主分支癌栓的肝癌的疗效比较[J].广东医学,2018,39(8):1213-1217,1222,6.基金项目
国家重点研发计划项目(编号:2017YFA0505803),国家杰出青年科学基金项目(编号:81625017),国家自然科学基金面上项目(编号:81572385) （编号:2017YFA0505803）
